Revolution Medicines

Biomarkers

• KRAS G12D6
• KRAS G12C3

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

daraxonrasib 9zoldonrasib 7elironrasib 4pembrolizumab 2cetuximab 2ivonescimab 1bevacizumab 1

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

• 2027-05 Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS Phase 1/2 · KRAS G12C, KRAS G12D
• 2027-06 Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC Phase 1/2 · KRAS G12C, KRAS G12D

Trials

12 of 15 trials shown

1. Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

   Recruiting Phase 3 Revolution Medicines Started 2026Primary completion 2029-03 NCT07805954

   daraxonrasibgemcitabinenab-paclitaxelzoldonrasib

   …ib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

   KRAS G12DPancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma

2. Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

   Recruiting Phase 3 Revolution Medicines Started 2026Primary completion 2029-10 NCT07777822

   zoldonrasibpembrolizumabpemetrexedcisplatincarboplatin

   …herapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

   KRAS G12DNSCLC, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer NSCLC, Non-Squamous Non Small Cell Lung Cancer

3. Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

   Recruiting Phase 3 Revolution Medicines Started 2026Primary completion 2028-12 NCT07621718

   zoldonrasiboxaliplatinleucovorinfluorouracilirinotecangemcitabinenab-paclitaxel

   … Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

   KRAS G12DPancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma

4. Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

   Recruiting Phase 3 Revolution Medicines Started 2025Primary completion 2027-12 NCT06881784

   daraxonrasibdocetaxel

   Documented RAS mutation status, defined as Nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61).

   KRAS G12CKRAS G12DNSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)

5. Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

   Active, not recruiting Phase 3 Revolution Medicines Started 2024Primary completion 2026-06 NCT06625320

   daraxonrasibgemcitabinenab-paclitaxelirinotecanliposomal irinotecanfluorouracilleucovorinoxaliplatin

   RAS mutations defined as nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, …

   KRAS G12CKRAS G12DPancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma

6. Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

   Recruiting Phase 1/2 Revolution Medicines Started 2026Primary completion 2029-05 NCT07397338

   daraxonrasibelironrasibzoldonrasibivonescimabcarboplatincisplatinpemetrexedcetuximab

   …ogically confirmed, locally advanced or metastatic solid tumor malignancy with documented RAS mutation in KRAS, HRAS, or NRAS.

   KRAS G12CKRAS G12DAdvanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC

7. Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

   Recruiting Phase 1/2 Revolution Medicines Started 2024Primary completion 2027-06 NCT06162221

   elironrasibdaraxonrasibpembrolizumabcisplatincarboplatinpemetrexedzoldonrasib

   Must have pathologically documented, locally advanced or metastatic KRAS G12C-mutated solid tumor malignancy (not amenable to curative surgery) (Subprotocol A)

   KRAS G12CKRAS G12DNon-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer

8. Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

   Recruiting Phase 1/2 Revolution Medicines Started 2024Primary completion 2028-09 NCT06445062

   daraxonrasibmFOLFOX6bevacizumabmFOLFIRINOXcetuximabgemcitabinenab-paclitaxelzoldonrasibFOLFIRI

   …reatic carcinoma or poorly differentiated pancreatic carcinoma with metastatic disease or RAS-mutated, histologically or cytologically confirmed colorectal adenocarcinoma with documented unre…

   KRAS G12CKRAS G12DColorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC

9. Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

   Recruiting Phase 1/2 Revolution Medicines Started 2023Primary completion 2028-12 NCT06128551

   elironrasibdaraxonrasib

   Histology: pathologically documented, KRAS G12C-mutated, advanced or metastatic solid tumors not amendable to curative therapy

   KRAS G12CNon-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma

10. Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

    Recruiting Phase 1/2 Revolution Medicines Started 2022Primary completion 2027-05 NCT05379985

    daraxonrasib

    …ally confirmed advanced solid tumor with specific KRAS G12 mutations (dose escalation) or RAS mutations (dose optimization/expansion) identified through deoxyribonucleic acid (DNA) sequencing.

    KRAS G12CKRAS G12DNon-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors

11. Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

    Recruiting Phase 1 Revolution Medicines Started 2023Primary completion 2026-12 NCT06040541

    zoldonrasibdaraxonrasib

    Pathologically documented, locally advanced or metastatic solid tumor with a KRAS G12D-mutation

    KRAS G12DNon-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors

12. Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

    Active, not recruiting Phase 1 Revolution Medicines Started 2022Primary completion 2027-03 NCT05462717

    elironrasib

    Subject must have pathologically documented, locally advanced or metastatic KRASG12C-mutated solid tumor malignancy (not amenable to curative surgery) that has previously bee…

    KRAS G12CNon-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor

No trials match these filters.